Literature DB >> 24814660

HIV and visceral leishmaniasis coinfection in Bihar, India: an underrecognized and underdiagnosed threat against elimination.

Sakib Burza1, Raman Mahajan1, Marta Gonzalez Sanz1, Temmy Sunyoto1, Ranjeet Kumar2, Gaurab Mitra2, María Angeles Lima3.   

Abstract

Although human immunodeficiency virus (HIV) and visceral leishmaniasis coinfection is recognized as a major public health challenge in Africa, data regarding the prevalence in India are very limited. Consecutive HIV screening of 2077 patients aged ≥14 years with confirmed visceral leishmaniasis in Bihar, eastern India, found that 5.6% were HIV positive, including 2.4% with newly diagnosed HIV infection.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV; India; Visceral leishmaniasis; kala-azar; prevalence

Mesh：

Year:  2014        PMID： 24814660     DOI： 10.1093/cid/ciu333

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  24 in total

Review 1.  Recent developments and future prospects in the treatment of visceral leishmaniasis.

Authors:  Shyam Sundar; Anup Singh
Journal:  Ther Adv Infect Dis       Date:  2016-04-22

Review 2.  An update on pharmacotherapy for leishmaniasis.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  Expert Opin Pharmacother       Date:  2014-10-25       Impact factor: 3.889

3.  Protective Efficacy of Secondary Prophylaxis Against Visceral Leishmaniasis in Human Immunodeficiency Virus Coinfected Patients Over the Past 10 Years in Eastern India.

Authors:  Rama P Goswami; Rudra P Goswami; Ayan Basu; Yogiraj Ray; Mehebubar Rahman; Santanu K Tripathi
Journal:  Am J Trop Med Hyg       Date:  2016-11-22       Impact factor: 2.345

Review 4.  Chemotherapeutics of visceral leishmaniasis: present and future developments.

Authors:  Shyam Sundar; Anup Singh
Journal:  Parasitology       Date:  2017-12-07       Impact factor: 3.234

Review 5.  Visceral leishmaniasis elimination targets in India, strategies for preventing resurgence.

Authors:  Shyam Sundar; Om Prakash Singh; Jaya Chakravarty
Journal:  Expert Rev Anti Infect Ther       Date:  2018-10-10       Impact factor: 5.091

6.  Visceral leishmaniasis.

Authors:  Shyam Sundar
Journal:  Trop Parasitol       Date:  2015 Jul-Dec

7.  Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India.

Authors:  Raman Mahajan; Pradeep Das; Petros Isaakidis; Temmy Sunyoto; Karuna D Sagili; Marıa Angeles Lima; Gaurab Mitra; Deepak Kumar; Krishna Pandey; Jean-Pierre Van Geertruyden; Marleen Boelaert; Sakib Burza
Journal:  Clin Infect Dis       Date:  2015-06-30       Impact factor: 9.079

Review 8.  PKDL and other dermal lesions in HIV co-infected patients with Leishmaniasis: review of clinical presentation in relation to immune responses.

Authors:  Eduard E Zijlstra
Journal:  PLoS Negl Trop Dis       Date:  2014-11-20

9.  Visceral leishmaniasis and HIV coinfection: time for concerted action.

Authors:  Johan van Griensven; Ed E Zijlstra; Asrat Hailu
Journal:  PLoS Negl Trop Dis       Date:  2014-08-28

10.  Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome).

Authors:  Sakib Burza; Raman Mahajan; Prabhat K Sinha; Johan van Griensven; Krishna Pandey; María Angeles Lima; Marta Gonzalez Sanz; Temmy Sunyoto; Sunil Kumar; Gaurab Mitra; Ranjeet Kumar; Neena Verma; Pradeep Das
Journal:  PLoS Negl Trop Dis       Date:  2014-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.